Tixagevimab plus cilgavimab for preventing COVID-19

  • Technology appraisal guidance
  • TA900
  • Published: 
Download guidance (PDF)

2 Information about tixagevimab plus cilgavimab

Marketing authorisation indication

2.1 Tixagevimab plus cilgavimab (Evusheld, AstraZeneca) has a conditional marketing authorisation for 'the pre‑exposure prophylaxis of COVID‑19 in adults who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2 and:

  • who are unlikely to mount an adequate immune response to COVID‑19 vaccination, or

  • for whom COVID‑19 vaccination is not recommended.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for tixagevimab plus cilgavimab.

Price

2.3 The list price of tixagevimab plus cilgavimab is £800 per 300 mg dose and £1,600 per 600 mg dose (excluding VAT; prices provided by company).

2.4 The company has a commercial arrangement, which would have applied if tixagevimab plus cilgavimab had been recommended.